Regulus Therapeutics (NASDAQ:RGLS) Upgraded at Wall Street Zen

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) was upgraded by investment analysts at Wall Street Zen to a "hold" rating in a research note issued on Friday.

A number of other equities analysts also recently commented on RGLS. Leerink Partnrs downgraded Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $9.00 target price on shares of Regulus Therapeutics in a report on Thursday, May 1st. Canaccord Genuity Group reiterated a "hold" rating and issued a $11.00 price target (down from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday, March 14th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Stock Performance

Shares of Regulus Therapeutics stock remained flat at $8.16 on Friday. Regulus Therapeutics has a 52 week low of $0.83 and a 52 week high of $8.35. The company has a market cap of $564.92 million, a price-to-earnings ratio of -11.18 and a beta of 0.35. The firm's 50-day moving average price is $7.14 and its two-hundred day moving average price is $3.41.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.14. On average, analysts expect that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Preston Klassen acquired 12,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were acquired at an average price of $7.99 per share, with a total value of $95,880.00. Following the acquisition, the insider now directly owns 48,055 shares in the company, valued at approximately $383,959.45. The trade was a 33.28% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.35% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RGLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Regulus Therapeutics by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 1,644 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in Regulus Therapeutics during the 1st quarter valued at $96,000. PEAK6 LLC bought a new stake in Regulus Therapeutics during the 4th quarter valued at $95,000. AQR Capital Management LLC acquired a new position in Regulus Therapeutics during the 1st quarter worth $120,000. Finally, Velan Capital Investment Management LP bought a new position in shares of Regulus Therapeutics in the fourth quarter worth $111,000. Institutional investors own 92.38% of the company's stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.